Yakira Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Yakira Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,333	Closed	-$828K	–	394
2021 Q2	$828K	Hold	8,333	–	–	0.13%	169
2021 Q1	$827K	Hold	8,333	–	–	0.17%	143
2020 Q4	$834K	Hold	8,333	–	–	0.2%	130
2020 Q3	$827K	Buy	+8,333	New	+$833K	0.24%	110

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Yakira Capital Management's JSPR Position: Q3 2021 in Review

Yakira Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 8,333 shares — an estimated $828K sold.

Yakira Capital Management first reported a position in JSPR in Q3 2020 and held it in 4 quarters. The position peaked at $834K in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Yakira Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Yakira Capital Management sold 8,333 Jasper Therapeutics shares in Q3 2021, an estimated $828K.
Yakira Capital Management first reported a position in Jasper Therapeutics in Q3 2020 and held it in 4 quarters.
Yakira Capital Management's Jasper Therapeutics position peaked at $834K in Q4 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Yakira Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.